Castle Biosciences Study Shows TissueCypher Nearly Doubles Appropriate Care Escalation for High-Risk Barrett's Esophagus Patients — Castle Biosciences, Inc.

Event summary

Castle Biosciences published a decision modeling study showing TissueCypher® significantly improved risk-aligned management for Barrett's esophagus patients.
The study simulated 699 patients and found TissueCypher increased appropriate management from 59.8% to 75.3% (P<0.001).
For non-dysplastic Barrett's esophagus patients who progressed to cancer, TissueCypher nearly doubled appropriate care escalation from 30.4% to 56.9% (P=0.001).
The study was published in the Annals of Gastroenterology on September 15, 2026.

The big picture

The study underscores the growing importance of precision medicine in gastroenterology, particularly for pre-malignant conditions like Barrett's esophagus where current surveillance protocols often lead to overtreatment. Castle Biosciences is positioning TissueCypher as a key tool in personalized care strategies, potentially reshaping how high-risk patients are managed. The findings come as diagnostic companies increasingly focus on AI-derived spatialomics to improve early cancer detection and risk assessment.

What we're watching

Clinical Adoption: Whether gastroenterologists will widely adopt TissueCypher given its demonstrated ability to reduce overtreatment and undertreatment.
Reimbursement Dynamics: The pace at which payers will cover TissueCypher testing, given its potential to reduce costly unnecessary procedures.
Competitive Positioning: How Castle Biosciences will differentiate TissueCypher in a market with emerging competing risk stratification tools.